Literature DB >> 10571074

A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs.

T Ishida1, D L Iden, T M Allen.   

Abstract

We have developed a method for producing sterically stabilized immunoliposomal drugs (SIL) readily applicable to a 'mix and match' combinatorial approach for the simple manufacture of a variety of ligand-targeted liposomal drugs. Ligands coupled to the terminus of polyethylene glycol (PEG) in micelles formed from PEG-lipid derivatives (mPEG2000-DSPE) could be transferred into preformed, drug-containing liposomes from the micelles in a temperature- and time-dependent manner. Antibody densities up to 100 microg antibody/micromol of phospholipid, and up to 3 mol% of mPEG2000-DSPE, could be simultaneously transferred from the ligand-coupled micelles into the liposomal outer monolayer with negligible drug leakage from liposomes during transfer and good stability in human plasma. Transfer of anti-CD19 into SIL resulted in a three-fold increase in binding of these liposomes to CD19+ human B cell lymphoma cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571074     DOI: 10.1016/s0014-5793(99)01320-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  41 in total

Review 1.  The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.

Authors:  W W Cheng; T M Allen
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

2.  Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.

Authors:  Xiaogang Pan; Gong Wu; Weiliang Yang; Rolf F Barth; Werner Tjarks; Robert J Lee
Journal:  Bioconjug Chem       Date:  2007 Jan-Feb       Impact factor: 4.774

3.  Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.

Authors:  Yunching Chen; Joyeeta Sen; Surendar Reddy Bathula; Qi Yang; Raffaella Fittipaldi; Leaf Huang
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

4.  Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors.

Authors:  Markus Gantert; Felicitas Lewrick; Joanna E Adrian; Jochen Rössler; Thomas Steenpass; Rolf Schubert; Regine Peschka-Süss
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

5.  Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer.

Authors:  Swati Biswas; Pranali P Deshpande; Federico Perche; Namita S Dodwadkar; Shailendra D Sane; Vladimir P Torchilin
Journal:  Cancer Lett       Date:  2013-02-16       Impact factor: 8.679

6.  Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model.

Authors:  Tatsuaki Tagami; Amr S Abu Lila; Mariko Matsunaga; Naoto Moriyoshi; Hiroyuki Nakamura; Kazuya Nakamura; Takuya Suzuki; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

7.  Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.

Authors:  Erez Koren; Anjali Apte; Ankur Jani; Vladimir P Torchilin
Journal:  J Control Release       Date:  2011-12-13       Impact factor: 9.776

8.  Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.

Authors:  Swati Biswas; Namita S Dodwadkar; Pranali P Deshpande; Shruti Parab; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2013-01-17       Impact factor: 5.571

9.  Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution.

Authors:  Chung-Gyu Park; Natalie W Thiex; Kyung-Mi Lee; Gregory L Szot; Jeffery A Bluestone; Kyung-Dall Lee
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

10.  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

Authors:  Robert T O'Donnell; Shiloh M Martin; Yunpeng Ma; William C Zamboni; Joseph M Tuscano
Journal:  Invest New Drugs       Date:  2009-03-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.